Jonathan Cairns
AstraZeneca (United Kingdom) · 103 works · 3,481 citations · h-index 22
Top works
- Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters
- CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- Lineage-specific dynamic and pre-established enhancer–promoter contacts cooperate in terminal differentiation
- BASH: a tool for managing BeadArray spatial artefacts
- Dynamic Rewiring of Promoter-Anchored Chromatin Loops during Adipocyte Differentiation
- Global reorganisation of cis-regulatory units upon lineage commitment of human embryonic stem cells
- CHiCAGO: Robust Detection of DNA Looping Interactions in Capture Hi-C data
- Integrated in vitro models for hepatic safety and metabolism: evaluation of a human Liver-Chip and liver spheroid
- BayesPeak—an R package for analysing ChIP-seq data
- Long-Range Enhancer Interactions Are Prevalent in Mouse Embryonic Stem Cells and Are Reorganized upon Pluripotent State Transition
- Chromosome contacts in activated T cells identify autoimmune disease candidate genes
- The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
- RNA proximity sequencing reveals the spatial organization of the transcriptome in the nucleus
- Phenotype Specific Analyses Reveal Distinct Regulatory Mechanism for Chronically Activated p53
- Platelet function is modified by common sequence variation in megakaryocyte super enhancers
- A statistical simulation model to guide the choices of analytical methods in arrayed CRISPR screen experiments
- The global and promoter-centric 3D genome organization temporally resolved during a circadian cycle
- Chromosome contacts in activated T cells identify autoimmune disease candidate genes
- Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development